作者
Alec B O’Connor, Dennis C Turk, Robert H Dworkin, Nathaniel P Katz, Robert Colucci, Jennifer A Haythornthwaite, Michael Klein, Charles O’Brien, Kelly Posner, Bob A Rappaport, Gary Reisfield, Edgar H Adams, Robert L Balster, George E Bigelow, Laurie B Burke, Sandra D Comer, Edward Cone, Penney Cowan, Richard A Denisco, John T Farrar, Richard W Foltin, J David Haddox, Sharon Hertz, Gary W Jay, Roderick Junor, Ernest A Kopecky, Deborah B Leiderman, Michael P McDermott, Pamela P Palmer, Srinivasa N Raja, Christine Rauschkolb, Michael C Rowbotham, Cristina Sampaio, Beatrice Setnik, Shannon M Smith, Marta Sokolowska, Joseph W Stauffer, Sharon L Walsh, James P Zacny
发表日期
2013/11/1
来源
PAIN®
卷号
154
期号
11
页码范围
2324-2334
出版商
No longer published by Elsevier
简介
Assessing and mitigating the abuse liability (AL) of analgesics is an urgent clinical and societal problem. Analgesics have traditionally been assessed in randomized clinical trials (RCTs) designed to demonstrate analgesic efficacy relative to placebo or an active comparator. In these trials, rigorous, prospectively designed assessment for AL is generally not performed. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) convened a consensus meeting to review the available evidence and discuss methods for improving the assessment of the AL of analgesics in clinical trials in patients with pain. Recommendations for improved assessment include: (1) performing trials that include individuals with diverse risks of abuse; (2) improving the assessment of AL in clinical trials (eg, training study personnel in the principles of abuse and addiction behaviors, designing the trial to assess …
学术搜索中的文章
AB O'Connor, DC Turk, RH Dworkin, NP Katz… - PAIN®, 2013